Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2004 Dec 7;92(1):30–35. doi: 10.1038/sj.bjc.6602271

p53 polymorphisms associated with mutations in and loss of heterozygosity of the p53 gene in male oral squamous cell carcinomas in Taiwan

L-L Hsieh 1,8,*, T-H Huang 2, I-H Chen 3,8, C-T Liao 3,8, H-M Wang 4,8, C-H Lai 1,2, S-H Liou 5, J T-C Chang 6,8, A-J Cheng 7,8
PMCID: PMC2361746  PMID: 15583690

Abstract

The present study was designed to examine whether different p53 haplotypes of exon 4–intron 3–intron 6 affect the frequency of mutations and loss of heterozygosity (LOH) of the p53 gene in male oral squamous cell carcinomas (OSCCs) in Taiwan. We found that individuals without two Pro-W-G alleles had significantly higher frequency of p53 mutations than those with two Pro-W-G alleles (odds ratio (OR)=1.98; 95% confidence interval (CI), 1.10–3.56). Out of the 172 p53 gene exon 4 informative male OSCCs, 72 (41.9%) showed LOH. Among these 72 OSCCs with LOH, the frequency of Pro allele loss was 73.6% (53/72). It is notable that alcohol drinking increased the frequency of Arg allele loss (OR=10.56; 95% CI, 1.23–234.94) in OSCCs from patients who both smoked cigarettes and chewed areca quid (AQ). The frequency of LOH of p53 was not different between p53-mutated OSCCs and p53-normal OSCCs. Thus, the present study revealed that (a) the Arg allele is associated with p53 mutations, (b) the Pro allele is preferentially lost in OSCCs associated with cigarette smoking and AQ chewing, while the frequency of Arg allele loss is increased with alcohol drinking, and (c) haploinsufficiency of p53 is in itself likely to contribute to tumour progression in Taiwanese OSCCs.

Keywords: oral squamous cell carcinoma, p53 , polymorphism, mutation, loss of heterozygosity

Oral cancer is the sixth most common cancer in the world (Nair et al, 1996), and was accounted to be the fifth leading cause of male cancer mortality in Taiwan in 2002 (Department of Health, ROC, 2003). Epidemiological studies have clearly indicated that areca quid (AQ) chewing, cigarette smoking and alcohol are the major risk factors for oral squamous cell carcinoma (OSCC) (IARC, 1985; Ko et al, 1995). In Taiwan, approximately 80% of all oral cancer patients are associated with the AQ chewing habit (Ko et al, 1995). In addition, most Taiwanese AQ chewers are also smokers and alcohol drinkers.

The p53 tumour suppressor protein is involved in cell-cycle control, apoptosis and DNA repair (Vogelstein et al, 2000). The importance of the p53 tumour suppressor gene in the process of carcinogenesis is well established (Hussain and Harris, 1998). Mutation at p53 has been demonstrated in over 50% of human cancers, especially tobacco-related cancers. Recently, we reported an important contributive role for tobacco carcinogens in p53 mutation for a series of Taiwanese patients with OSCCs (Hsieh et al, 2001). The most prevalent types of p53 mutation found in Taiwanese OSCCs were G:C to A:T transitions and G:C to T:A transversions. Studies have demonstrated that these types of mutations are the most common mutations observed in animals treated with NNK or other tobacco nitrosamines (Belinsky et al, 1991; Oreffo et al, 1993; Ronai et al, 1993; Chang et al, 1996). Evidence from the literature also indicates that NNK-associated DNA adducts, in addition to being repaired by the nucleotide excision repair pathway, are also repaired by base excision repair (Cloutier and Castonguay, 1998). XRCC1 plays an important role in the base excision repair pathway, and interacts with DNA polymerase β, PARP and DNA ligase III. It also has a BRCT domain, which is characteristic of proteins involved in cycle checkpoint functions and this domain may be responsive to DNA damage (Caldecott et al, 1996; Masson et al, 1998). Abdel-Rahman and El-Zein (2000) found that the 399Gln polymorphism of XRCC1 appeared to be associated with reduced repair of NNK-induced genetic damage in cultured human lymphocytes. We found that OSCC patients with an XRCC1 399Gln/Gln genotype exhibited a significantly higher frequency of p53 mutation than those with an Arg/Gln or an Arg/Arg genotype (Hsieh et al, 2003).

It is known that one type of p53 polymorphism that is found in the general population results in either an Arg or a Pro at residue 72 and this produces a marked change in the structure of the p53 protein (Matlashewski et al, 1987). Recently, Marin et al (2000) and Tada et al (2001) have reported that the Arg72 allele was preferentially mutated and retained in various human tumours. In addition to codon 72 polymorphism, Wu et al (2002) found that cells with different p53 haplotypes of exon 4–intron 3–intron 6 showed different capacities for DNA repair and apoptosis. In this study, we test whether different p53 haplotypes of exon 4–intron 3–intron 6 would associate with p53 mutations and examine the role of the Arg72 allele in loss of heterozygosity (LOH) of p53 gene in Taiwanese OSCCs.

MATERIALS AND METHODS

Patients, tissue specimens and clinical diagnosis

This study was approved by the Institutional Review Board, Chang Gung Memorial Hospital. A total of 715 OSCC patients treated at Chang Gung Memorial Hospital, Lin-Kuo during the period from March 1999 to December 2001 were recruited consecutively for participation in the present study. All cases were histologically confirmed. Female patients (n=42) were excluded from this study because of an insufficient number. Those who were diagnosed as nonsquamous cell carcinoma (n=44) were also excluded. Thus, a total of 629 male OSCC patients, including 237 patients previously studied (Hsieh et al, 2003), were included for the present analysis. All patients gave informed consent for participation and were interviewed uniformly before surgery by a well-trained interviewer. The questionnaire used in the interview sought detailed information on current and past cigarette smoking, alcohol drinking and AQ chewing habits, occupational history, family disease history, dietary history and general demographic data.

For each case, two samples were taken, a tumour sample and a sample from the adjacent normal nontumour tissue. These samples were surgically dissected into small pieces, frozen immediately in liquid nitrogen and stored at −80°C. In addition, 10 ml of venous blood was drawn into heparinised tubes (Vacutainer) and stored at 4°C. The whole blood was separated into plasma, buffy coat cells and red blood cells by centrifugation within 18 h of obtaining the blood, and stored in a −80°C freezer. Genomic DNA for genotyping was extracted and purified from the buffy coat cells as previously described (Hsieh et al, 2003).

The surgically removed samples were sent to the Department of Pathology, Chang Gung Medical Center for examination and scored according to the recommendations for the reporting of specimens containing oral cavity and oropharynx neoplasms by the Associations of Directors of Anatomic and Surgical Pathology (ADASP) (2000). Histology diagnosis was defined as squamous cell carcinoma, verrucous carcinoma, cylindric cell carcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma and adenocarcinoma.

As reference male controls, 371 subjects with available blood samples selected from 3000 random samples of the Taiwanese general population collected to study blood lead concentrations were included in this study (Hsieh et al, 2000).

Tobacco, AQ and alcohol use

Study participants were asked if they had ever smoked cigarettes, chewed AQ or drank alcohol on a regular basis (at least once a week for 1 year). Those who responded ‘yes’ to these questions were classified as tobacco, AQ and alcohol users, respectively.

p53 genotype and haplotype determination

The genotype of p53 for intron 3, exon 4 and intron 6 was determined by PCR-RFLP (Wu et al, 2002) followed by polyacrylamide gel electrophoresis. For the exon 4 codon 72 polymorphism, a 396 bp DNA fragment was amplified and digested with BstUI. The Arg/Arg homozygotes showed two bands of 165 and 231 bp, the Arg/Pro heterozygotes showed three bands of 165, 231 and 396 bp and the Pro/Pro homozygotes showed only one band of 396 bp. For the intron 3 polymorphism, either a 180 or 196 bp DNA fragment was amplified. The WW (without the 16 bp duplication) homozygotes showed one band of 180 bp, the WM heterozygotes showed two bands of 180 and 196 bp and the MM (with the 16 bp duplication) homozygotes showed only one band of 196 bp. For the intron 6 polymorphism, a 404 bp DNA fragment was amplified and digested with MspI. The GG homozygotes showed two bands of 68 and 336 bp, the GA heterozygotes showed three bands of 68, 336 and 404 bp and the AA homozygotes showed only one band of 404 bp.

p53 haplotypes could be inferred directly from the genotyping results for the individuals who were heterozygous at only one site or at no sites. For the other individuals, allele cloning and PCR-RFLP methods were used to determine the haplotypes. A 1.6 kb fragment of p53 gene containing intron 3, exon 4 and intron 6 was amplified, cloned with the pCR® 2.1 vector (Invitrogen, Carlsbad, CA, USA) and transformed into INVαF′ cells. At least five white clones of each case were genotyped for intron 3, exon 4 and intron 6 by PCR-RFLP as described above.

Mutation and LOH analysis of the p53 gene

According to Soussi and Beroud (2001), 13.6% of p53 mutations were located outside exons 5–8, with a significant number of mutations in exons 4, 10 and, to a lesser extent, 9. Therefore, single-stranded conformation polymorphism (SSCP) analysis was used to analyse tumour samples for mutations within exons 4–10 of the p53 gene. The lengths of PCR fragments for our SSCP analysis were in the range of 135–245 bp and the sensitivity and specificity of this technique to detect mutations even if only present in a low amount is more than 90%. Cases displaying an altered electrophoretic mobility were reamplified in another reaction and analysed by direct sequencing of both strands to confirm and characterise the nature of the mutation (Hsieh et al, 2001).

For individuals who were heterozygous at exon 4 codon 72, DNA from their tumour tissues was used to amplify the 396 bp exon 4 fragment, which was digested with BstUI, purified and analysed by denaturing high-performance liquid chromatography (DHPLC) (WAVE DNA Fragment Analysis System, Omaha, NE, USA) (Kleymenova and Walker, 2001). PCR was performed for 27 cycles so that the reaction was still in the exponential phase of amplification. Then, DHPLC analysis was performed at 50°C and flow rate 0.9 ml min−1 in a gradient of acetonitrile in 0.1 M triethylammonium acetate: the gradient started at 8.75%, increased in 3.5 min to 13.75%, then increased in 7 min to 16.25%, was constant for 1 min, then increased in 1 min to 75%, was constant for 1 min (wash), then decreased in 1 min to 8.75% and finally was constant for 1 min (equilibration). The ratio of the peak area between the 396 bp fragment, the Pro allele, and the 231 bp fragment, the Arg allele, was calculated. Tumour DNA with a ratio outside the 95% confidence interval (CI) of the mean ratio from 30 normal controls was considered as positive for LOH in the p53 gene (representative results by DHPLC are shown in Figure 1).

Figure 1.

Figure 1

Open in a new tab

LOH analysis of p53 gene by DHPLC. The analysis was performed at 50°C and flow rate 0.9 ml min−1 in a gradient of acetonitrile in 0.1 M triethylammonium acetate: the gradient started at 8.75%, increased in 3.5 min to 13.75%, then increased in 7 min to 16.25%, was constant for 1 min, then increased in 1 min to 75%, was constant for 1 min (wash), then decreased in 1 min to 8.75% and finally was constant for 1 min (equilibration).

STATISTICAL ANALYSIS

Statistical analyses were performed with the Statistical Analysis System (SAS) version 8.1. The association between the frequency of p53 mutation or LOH and genotype/haplotype of p53 intron 3, exon 4 and intron 6 was examined by χ2 or Fisher's exact test. Multiple logistic regression model was further used to assess the major factors attributed to the frequency of p53 mutation.

RESULTS

A total of 629 consecutive patients with a diagnosis of OSCC were enrolled in the study. The demographic information of the patients is shown in Table 1. The most common primary sites were the bucca and the tongue. In all, 94% (591/628) of the patients had smoked at some time, 62.4% (389/623) were users of alcohol at some time and 90.8% (570/628) had chewed AQ at some time.

Table 1. Characteristics of the male patients with OSCCs (n=629).

Age (years)  
 Mean±s.d. 49.93±10.67
 Range 25–78
   
Site of primary tumour (N (%))  
 Oral cavity 523 (83.2)
  Lip 19 (3.0)
  Tongue 175 (27.8)
  Mouth floor 22 (3.5)
  Buccal mucosa 208 (33.1)
  Gingiva 53 (8.4)
  Hard palate 13 (2.1)
  Retromolar trigone 33 (5.2)
 Oropharynx 49 (7.8)
 Hypopharynx 57 (9.1)
   
Clinical stage (N (%))  
 Stage I 79 (12.8)
 Stage II 136 (22.1)
 Stage III 125 (20.3)
 Stage IV 275 (44.7)
   
Cigarette smoker at some time (N (%)) 591 (94.1)
Alcohol drinker at some time (N (%)) 389 (62.4)
Areca quid chewer at some time (N (%)) 570 (90.8)
Open in a new tab

As shown in Table 2, the frequencies of Arg72, W allele of intron 3 and G allele of intron 6 were 0.58, 0.97 and 0.97, respectively, in the referent male controls. The frequencies of the Arg/Arg, Arg/Pro and Pro/Pro genotypes for codon 72 were 34.50, 47.71 and 17.79%, respectively. The frequencies of the WW, WM and MM genotypes for intron 3 were 94.07, 5.39 and 0.54%, respectively. The frequencies of the GG, GA and AA genotypes for intron 6 were 94.07, 5.39 and 0.54%, respectively. All of the distributions were in Hardy–Weinberg equilibrium. The most common two haplotypes of exon 4–intron 3–intron 6 were Arg-W-G (58.36%), followed by Pro-W-G (38.41%). All other types were relatively rare. It is interesting to note that these rare haplotypes were slightly associated with a risk of oral cancer (odds ratio (OR)=1.72; 95% CI, 0.97–3.07).

Table 2. Risk estimates for p53 haplotypes in male OSCC patients and control subjects.

Inline graphic
Open in a new tab

aOther OSCC patients: including oropharynx and hypopharynx cancer patients.

bW: common allele (without replicative 16 bp); M : rare allele (with replicative 16 bp).

Tumour samples from 272 OSCC patients without antecedent treatment, including 237 cases published previously (Hsieh et al, 2001), were examined for mutations within exons 4–10 of the p53 gene by PCR-SSCP. Based on Table 2, the associations between the common haplotypes of p53 gene and cancer risk were slightly different in different sites of oral cancer (oral cavity cancer vs hypopharyngeal/oropharyngeal cancer). The cases of hypopharyngeal and oropharyngeal cancer were excluded for statistical analysis (n=18). Of the 254 oral cavity OSCCs, 128 (50.4%) showed a p53 gene mutation at exons 4–10. Individuals with either one or no Pro-W-G alleles were more likely to have p53 gene mutations (OR=1.99; 95% CI, 1.08–3.68; Table 3) than those with two Pro-W-G alleles. After adjustment for age, cigarette smoking, alcohol drinking, AQ chewing and XRCC1 399Gln polymorphism, individuals with one or no Pro-W-G alleles still had a higher frequency of p53 mutations (OR=1.98; 95% CI, 1.10–3.56) than those with two Pro-W-G alleles.

Table 3. Association of p53 haplotypes and p53 gene mutations in oral cavity cancer.

Inline graphic
Open in a new tab

aAdjusted for age, cigarette smoking, alcohol drinking, AQ chewing and XRCC1 399Gln polymorphism.

Among the 128 OSCCs with p53 mutations by SSCP, 12 samples contained two different mutations of the p53 gene and 15 samples were not successfully sequenced. To reduce the complexity of interpretation, cases with two mutations were excluded from further analysis. Among the 101 mutations with an identified sequence, 16 (15.8%) were deletions or insertions, 53 (52.5%) were G:C to A:T transitions and 17 (16.8%) were G:C to T:A transversions. The forms of mutation were not significantly different between individuals with two Pro-W-G alleles and those with either one or no Pro-W-G alleles (data not shown).

Tumour samples from 172 informative male oral cavity cancer patients for p53 gene exon 4 were examined for LOH of the p53 gene. Of the 172 OSCCs, 72 (41.9%) showed LOH (Table 4). Among the 72 OSCCs with LOH of the p53 gene, Pro allele loss was found in 53 (73.6%) of the tumours. The frequency of LOH of p53 was not associated with age, cigarette smoking, AQ chewing or alcohol drinking. However, stage IV tumours had a slightly higher frequency (33/66, 50.0%) of p53 LOH than stage I–III tumours (39/106, 36.8%) (P=0.09 by χ2). It is also interesting to note that alcohol drinking would seem to increase the frequency of Arg allele loss (OR=10.56; 95% CI, 1.23–234.94) among cigarette smokers and AQ chewers.

Table 4. Stratification analysis of the risk factors for oral cavity cancer and the frequency of LOH of the p53 gene.

Inline graphic
Open in a new tab

The status of p53 gene mutation was known for 94 tumour samples from 172 informative male oral cavity cancer patients for p53 gene exon 4. Of the 94 OSCCs, 67 (71.3%) showed alterations (mutation, LOH or both) of p53 gene (Table 5). The frequency of LOH of p53 was not different between 46 p53-mutated OSCCs and 48 p53-normal OSCCs (52.2 vs 43.8%, P=0.41 by χ2). However, LOH was more likely to appear at late than early tumour stage (14 events for stage IV vs seven events for stage I–III), while mutation occurred at the early tumour stage (16 events for stage I–III vs six events for stage IV). Therefore, stage IV tumours had a slightly higher frequency (26/45, 57.8%) of p53 LOH than stage I–III tumours (19/49, 38.8%) (P=0.07 by χ2). Furthermore, a significant cumulative effect of mutation of p53 and tumour stage on LOH of p53 was observed (P=0.03 by χ2 trend test). It is also interesting to note that stage IV tumours had a slightly higher frequency (20/26, 76.9%) of Pro allele loss than stage I–III tumours (11/19, 57.9%) (P=0.17 by χ2) regardless of p53 mutation. The frequency of p53 mutation was not different between 31 OSCCs having Pro allele loss and 14 OSCCs with Arg allele loss (51.6 vs 57.1%, P=0.73 by χ2).

Table 5. Association of mutation of p53, tumour stage and the frequency of LOH of the p53 gene in oral cavity cancer.

Mutation of p53 Tumour stage LOH/informative cases (%) OR (95% CI)* Lost Pro allele/LOH cases (%) OR (95% CI)
No I–III 7/21 (33.3) 1 4/7 (57.1) 1
Yes I–III 12/28 (42.9) 1.50 (0.40–5.75) 7/12 (58.3)  
No IV 14/27 (51.0) 2.15 (0.57–8.35) 11/14 (78.6) 2.42 (0.56–10.77)
Yes IV 12/18 (66.7) 4.00 (0.88–19.32) 9/12 (75.0)  
Total   45/94 (47.9)   31/45 (68.9)  
Open in a new tab
*

P=0.03 by χ2 trend test.

DISCUSSION

p53 has a critical role in cell-cycle control, apoptosis and DNA repair (Vogelstein et al, 2000). Among the more than 10 DNA sequence polymorphisms identified, the codon 72 polymorphism (Arg/Pro) has been explored in depth for a potential association with cancer. Although this polymorphism has been implied to be associated with certain cancer types (Yu et al, 1999; Fan et al, 2000; Shepherd et al, 2000), Sun et al (1999) reviewed 31 epidemiological case–control studies and suggested that codon 72 allelism did not have an impact on human cancer risk. The present study found that there was no significant difference in the frequency of codon 72 genotype between patients and referent controls (P=0.27). Recently, five case–control studies have been conducted to investigate an association between the p53 codon 72 polymorphism and the risk of squamous cell carcinoma of the head and neck (SCCHN), but none of them have found a positive association (Hamel et al, 2000; McWilliams et al, 2000; Summersgill et al, 2000; Shen et al, 2002; Mitra et al, 2003). Taken together, these results suggested that codon 72 allelism does not seem to have an impact on human cancer risk, especially for SCCHN, although Dumont et al (2003) had demonstrated that the Arg72 form of p53 was at least five times better at inducing apoptosis than the Pro72 variant.

The difference in overall haplotype frequency between patients and referent controls was not significant in the present study (P=0.22). However, it is interesting to note that the rare haplotypes (rare allele in introns 3 and 6) were slightly associated with a risk of oral cancer (OR=1.72; 95% CI, 0.97–3.07) (Table 2). Recently, Gemignani et al (2004) have observed that a rare allele in intron 3 was associated with an increased risk of colorectal cancer and reduced basal levels of p53 mRNA in immortalised lymphoblastoid cell lines. Taken together, these results could support the speculation by Wu et al (2002) that introns 3 and 6 rare alleles might exert a functional effect, because as the copy number of the rare allele in introns 3 and 6 is increased, the level of the apoptotic index is decreased.

In Taiwan, most of male oral cavity cancer patients have a history of both habitual cigarette smoking and AQ chewing. In the present study, among 167 male OSCC patients informative for p53 gene exon 4, 141 (84.4%) have a history of both habitual cigarette smoking and AQ chewing. Among these 141 OSCC patients, 91 (64.5%) patients also had a history of habitual alcohol drinking. The frequency of LOH for p53 did not differ between patients with and without alcohol drinking. However, interestingly, almost all of the patients (95.5%, 21/22) without alcohol drinking had lost the Pro allele, whereas only 68.4% (26/38) of the patients with alcohol drinking had lost the Pro allele. In this study, we did not determine which allele was mutated in the p53-mutated oral cavity cancer patients with germline heterozygosity (Arg/Pro). Further studies to determine the biological mechanism by which there is selection for different codon 72 alleles by alcohol drinking are thus desirable.

In the present study, we found that OSCC patients with the Arg72 allele had a significantly higher frequency of p53 mutation than those with Pro/Pro genotype among patients with common alleles of introns 3 and 6 (OR=1.93; 95% CI, 1.03–3.63). In addition, 73.6% (53/72) of those who showed LOH of the p53 gene had lost the Pro allele. These results are consistent with those reported by other authors for some tumour types, in which it has been pointed out that LOH of p53 occurs more commonly for the Pro allele and that there is a preferential mutation of the Arg72 allele (Brooks et al, 2000; Marin et al, 2000; Tada et al, 2001; Furihata et al, 2002; Anzola et al, 2003). Based on the reports assigning a higher apoptotic potential to the Arg allele (Wu et al, 2002) and the current data, we could hypothesise that the cells carrying an Arg allele require further p53 mutations to increase their tumorigenic potential, while Pro/Pro cells could undergo this procedure with fewer damage. Indeed, Marin et al (2000) and Tada et al (2001) found that the p53 mutant acts as a more potent inhibitor of p73 activity when p53 has Arg72 rather than Pro72. Additional comprehensive studies using this series of samples will be needed to elucidate the association between polymorphisms within p53 and the mutant behaviour of p53 in OSCCs associated with cigarette smoking, AQ chewing and alcohol drinking.

The two-hit paradigm of tumour suppressor gene mutation has held sway for many years. Recently, Venkatachalam et al (1998) found that a high proportion of the tumours from the p53+/− mice retained an intact, functional, wild-type allele. This result indicates that mere reduction in p53 levels may be sufficient to promote tumorigenesis. Although p53 mutation accompanied by complete loss of the wild-type allele is the most frequent event observed in many human cancers (Greenblatt et al, 1994), we found no preference of mutation with LOH (n=24), mutation without LOH (n=22) or LOH without mutation (n=21) in 94 Taiwanese OSCCs with germline heterozygosity in codon 72 (Arg/Pro). Furthermore, LOH was more likely to appear at late than early tumour stage (14 for stage IV vs seven for stage I–III), while mutation was occurred at the early tumour stage (16 for stage I–III vs six for stage IV). These results support the hypothesis that haploinsufficiency of p53 is in itself likely to contribute to tumour progression and the mutant form of p53 has a dominant gain-of-function activity or it may block the wild-type protein by acting as a dominant negative (Santarosa and Ashworth, 2004).

In conclusion, we found that p53 codon 72 polymorphism may not be a dominant factor for predisposition to OSCCs in Taiwan. However, the present study revealed that (a) the Arg allele is associated with p53 mutations, (b) the Pro allele is preferentially lost in OSCCs associated with cigarette smoking and AQ chewing, while the frequency of Arg allele loss is increased with alcohol drinking, and (c) haploinsufficiency of p53 is in itself likely to contribute to tumour progression in Taiwanese OSCCs.

Acknowledgments

This study was supported by Grants NSC 89-2314-B182-096, NSC90-2320-B-182-055, NSC91-2320-B-182-024 and NSC92-2320-B-182-036 from the National Science Council and Grants NHRI-EX90-8802PP, NHRI-EX91-8802PP, NHRI-EX92-8802PP and NHRI-CN-IN-9005P from the National Health Research Institute, Department of Health, Executive Yuan, ROC.

References

  1. Abdel-Rahman SZ, El-Zein RA (2000) The 399Gln polymorphism in the DNA repair gene XRCC1 modulates the genotoxic response induced in human lymphocytes by the tobacco-specific nitrosamine NNK. Cancer Lett 159: 63–71 [DOI] [PubMed] [Google Scholar]
  2. Anzola M, Cuevas N, Lopez-Martinez M, Saiz A, Burgos JJ, de Pancorbo MM (2003) Frequent loss of p53 codon 72 Pro variant in hepatitis C virus-positive carriers with hepatocellular carcinoma. Cancer Lett 193: 199–205 [DOI] [PubMed] [Google Scholar]
  3. Association of Directors of Anatomic and Surgical Pathology (2000) Recommendations for the reporting of specimens containing oral cavity and oropharynx neoplasms. Mod Pathol 13: 1038–1041 [DOI] [PubMed] [Google Scholar]
  4. Belinsky SA, Devereux TR, White CM, Foley JF, Maronpot RR, Anderson MW (1991) Role of Clara cells and type II cells in the development of pulmonary tumors in rats and mice following exposure to a tobacco-specific nitrosamine. Exp Lung Res 17: 263–278 [DOI] [PubMed] [Google Scholar]
  5. Brooks LA, Tidy JA, Gusterson B, Hiller L, O’Nions J, Gasco M, Marin MC, Farrell PJ, Kaelin Jr WG, Crook T (2000) Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Res 60: 6875–6877 [PubMed] [Google Scholar]
  6. Caldecott KW, Aoufouchi S, Johnson P, Shall S (1996) XRCC1 polypeptide interacts with DNA polymerase beta and possibly poly (ADP-ribose) polymerase, and DNA ligase III is a novel molecular ‘nick-sensor’ in vitro. Nucleic Acids Res 24: 4387–4394 [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chang KW, Lin SC, Koos S, Pather K, Solt D (1996) p53 and Ha-ras mutations in chemically induced hamster buccal pouch carcinomas. Carcinogenesis 17: 595–600 [DOI] [PubMed] [Google Scholar]
  8. Cloutier JF, Castonguay A (1998) Modulation of DNA repair by various inhibitors of DNA synthesis following 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) induced DNA damage. Chem Biol Interact 110: 7–25 [DOI] [PubMed] [Google Scholar]
  9. Department of Health, ROC (2003) Health and Vital Statistics, Republic of China 2002. Taipei, ROC: Department of Health, Executive Yuan [Google Scholar]
  10. Dumont P, Leu JI, Della Pietra III AC, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33: 357–365 [DOI] [PubMed] [Google Scholar]
  11. Fan R, Wu MT, Miller D, Wain JC, Kelsey KT, Wiencke JK, Christiani DC (2000) The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 9: 1037–1042 [PubMed] [Google Scholar]
  12. Furihata M, Takeuchi T, Matsumoto M, Kurabayashi A, Ohtsuki Y, Terao N, Kuwahara M, Shuin T (2002) p53 mutation arising in Arg72 allele in the tumorigenesis and development of carcinoma of the urinary tract. Clin Cancer Res 8: 1192–1195 [PubMed] [Google Scholar]
  13. Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Gutierrez-Enriquez S, Hall J, Guino E, Peinado MA, Capella G, Canzian FA (2004) TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 23: 1954–1956 [DOI] [PubMed] [Google Scholar]
  14. Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855–4878 [PubMed] [Google Scholar]
  15. Hamel N, Black MJ, Ghadirian P, Foulkes WD (2000) No association between p53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck. Br J Cancer 82: 757–759 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hsieh LL, Chien HT, Chen I H, Liao CT, Wang HM, Jung SM, Wang PF, Chang JT, Chen MC, Cheng AJ (2003) The XRCC1 399Gln polymorphism and the frequency of p53 mutations in Taiwanese oral squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev 12: 439–443 [PubMed] [Google Scholar]
  17. Hsieh LL, Liou SH, Chen YH, Tsai LC, Yang T, Wu TN (2000) Association between aminolevulinate dehydrogenase genotype and blood lead levels in Taiwan. J Occup Environ Med 42: 151–155 [DOI] [PubMed] [Google Scholar]
  18. Hsieh LL, Wang PF, Chen IH, Liao CT, Wang HM, Chen MC, Chang JTC, Cheng AJ (2001) Characteristics of mutations in the p53 gene in oral squamous cell carcinoma associated with betel quid chewing and cigarette smoking in Taiwanese. Carcinogenesis 22: 1497–1503 [DOI] [PubMed] [Google Scholar]
  19. Hussain SP, Harris CC (1998) Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res 58: 4023–4037 [PubMed] [Google Scholar]
  20. IARC (1985) Betel-quid and Areca Nut Chewing. Lyon: IARC Scientific Publications [Google Scholar]
  21. Kleymenova E, Walker CL (2001) Determination of loss of heterozygosity in frozen and paraffin embedded tumors by denaturing high-performance liquid chromatography (DHPLC). J Biochem Biophys Methods 47: 83–90 [DOI] [PubMed] [Google Scholar]
  22. Ko YC, Huang YL, Lee CH, Chen MJ, Lin LM, Tsai CC (1995) Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan. J Oral Pathol Med 24: 450–453 [DOI] [PubMed] [Google Scholar]
  23. Marin MC, Jost CA, Brooks LA, Irwin MS, O’Nions J, Tidy JA, James N, McGregor JM, Harwood CA, Yulug IG, Vousden KH, Allday MJ, Gusterson B, Ikawa S, Hinds PW, Crook T, Kaelin Jr WG (2000) A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 25: 47–54 [DOI] [PubMed] [Google Scholar]
  24. Masson M, Niedergang C, Schreiber V, Muller S, Menissier-de Murcia J, de Murcia G (1998) XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol 18: 3563–3571 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV (1987) Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 7: 961–963 [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. McWilliams JE, Evans AJ, Beer TM, Andersen PE, Cohen JI, Everts EC, Henner WD (2000) Genetic polymorphisms in head and neck cancer risk. Head Neck 22: 609–617 [DOI] [PubMed] [Google Scholar]
  27. Mitra S, Chatterjee S, Panda CK, Chaudhuri K, Ray K, Bhattacharyya NP, Sengupta A, Roychoudhury S (2003) Haplotype structure of TP53 locus in Indian population and possible association with head and neck cancer. Ann Hum Genet 67(Part 1): 26–34 [DOI] [PubMed] [Google Scholar]
  28. Nair J, Ohshima H, Nair UJ, Bartsch H (1996) Endogenous formation of nitrosamines and oxidative DNA-damaging agents in tobacco users. Crit Rev Toxicol 26: 149–161 [DOI] [PubMed] [Google Scholar]
  29. Oreffo VI, Lin HW, Padmanabhan R, Witschi H (1993) K-ras and p53 point mutations in 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced hamster lung tumors. Carcinogenesis 14: 451–455 [DOI] [PubMed] [Google Scholar]
  30. Ronai ZA, Gradia S, Peterson LA, Hecht SS (1993) G to A transitions and G to T transversions in codon 12 of the Ki-ras oncogene isolated from mouse lung tumors induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and related DNA methylating and pyridyloxobutylating agents. Carcinogenesis 14: 2419–2422 [DOI] [PubMed] [Google Scholar]
  31. Santarosa M, Ashworth A (2004) Haploinsufficiency for tumour suppressor genes: when you don’t need to go all the way. Biochim Biophys Acta 1654: 105–122 [DOI] [PubMed] [Google Scholar]
  32. Shen H, Zheng Y, Sturgis EM, Spitz MR, Wei Q (2002) p53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case–control study. Cancer Lett 183: 123–130 [DOI] [PubMed] [Google Scholar]
  33. Shepherd T, Tolbert D, Benedetti J, Macdonald J, Stemmermann G, Wiest J, DeVoe G, Miller MA, Wang J, Noffsinger A, Fenoglio-Preiser C (2000) Alterations in exon 4 of the p53 gene in gastric carcinoma. Gastroenterology 118: 1039–1044 [DOI] [PubMed] [Google Scholar]
  34. Soussi T, Beroud C (2001) Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 1: 233–240 [DOI] [PubMed] [Google Scholar]
  35. Summersgill KF, Smith EM, Kirchner HL, Haugen TH, Turek LP (2000) p53 polymorphism, human papillomavirus infection in the oral cavity, and oral cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 90: 334–339 [DOI] [PubMed] [Google Scholar]
  36. Sun Y, Keshava C, Sharp DS, Weston A, McCanlies EC (1999) DNA sequence variants of p53: cancer and aging. Am J Hum Genet 65: 1779–1782 [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Tada M, Furuuchi K, Kaneda M, Matsumoto J, Takahashi M, Hirai A, Mitsumoto Y, Iggo RD, Moriuchi T (2001) Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants. Carcinogenesis 22: 515–517 [DOI] [PubMed] [Google Scholar]
  38. Venkatachalam S, Shi YP, Jones SN, Vogel H, Bradley A, Pinkel D, Donehower LA (1998) Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J 17: 4657–4667 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408: 307–310 [DOI] [PubMed] [Google Scholar]
  40. Wu X, Zhao H, Amos CI, Shete S, Makan N, Hong WK, Kadlubar FF, Spitz MR (2002) p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst 94: 681–690 [DOI] [PubMed] [Google Scholar]
  41. Yu MW, Yang SY, Chiu YH, Chiang YC, Liaw YF, Chen CJ (1999) A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology 29: 697–702 [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES